^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HQP8361

    i
    Other names: HQP8361, MK-8033
    Company:
    Ascentage Pharma, Merck (MSD)
    Drug class:
    c-MET inhibitor
    Related drugs:
    4years
    The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. (PubMed, Am J Cancer Res)
    HQP8361 (MK8033) is a novel and selective MET kinase inhibitor that has completed a phase I clinical trial. Moreover, the combination also very effectively inhibited the growth of HCC827/AR xenografts in nude mice. These preclinical findings support the potential of HQP8361 in the treatment of NSCLCs with MET amplification or highly activated MET and, when combined with AZD9291, in overcoming acquired resistance to EGFR-TKIs due to MET amplification.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • MCL1 (Myeloid cell leukemia 1)
    |
    EGFR mutation • MET amplification • EGFR T790M
    |
    Tagrisso (osimertinib) • HQP8361 • lovastatin